Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism
Abstract Direct acting antivirals against hepatitis C virus (HCV) have markedly improved cure rates in the past few years. However, they are expensive, with only few targeting host cell factors, and affecting virus assembly and release. Huh7.5 cells infected with a JFH-1 clone of HCV were treated wi...
Guardado en:
Autores principales: | Mohammed A. Sarhan, Mohamed S. Abdel-Hakeem, Andrew L. Mason, D. Lorne Tyrrell, Michael Houghton |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f51753bd6d524097863f80264b9246e4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
In vivo regulation of glycogen synthase kinase 3β activity in neurons and brains
por: Ambika Krishnankutty, et al.
Publicado: (2017) -
Immobilization of Glycogen Synthase Kinase-3β Inhibitor on 316L Stainless Steel via Polydopamine to Accelerate Endothelialization
por: Ming Zhang, et al.
Publicado: (2021) -
Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus
por: Sandra G. Gonzalez Malagon, et al.
Publicado: (2018) -
Snail regulation in fibroblast-like synoviocytes by a histone deacetylase or glycogen synthase kinase inhibitor affects cell proliferation and gene expression.
por: Po-Chuan Shen, et al.
Publicado: (2021) -
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice.
por: Xian-Cang Ma, et al.
Publicado: (2013)